

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

One stakeholder highlighted potential equality considerations for older patients with RRMM, noting that the condition predominantly affects later-life populations who often have comorbidities and related disabilities. They emphasised the need for the scope to support equitable access to effective treatments, address unmet need in heavily pre-treated RRMM, and recognise the benefits of reducing treatment burden through one-time infusion therapies compared with continuous, high-frequency treatments.

- | |
|---------------------------------------------------------------------------------------------------------------------|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---------------------------------------------------------------------------------------------------------------------|

In previous multiple myeloma evaluations, stakeholders have noted that the condition is common in men, older people, and people from Black African and Caribbean ethnic groups. The committee will consider whether any differences in prevalence would represent an equality issue.

- | |
|------------------------------------------------------------------------------------------|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|------------------------------------------------------------------------------------------|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

The following stakeholders have been identified and been added to the stakeholder list:

- African Caribbean Leukaemia Trust
- Cancer Equality

Approved by Associate Director: Emily Crowe...

Date: 04/06/2026